Orchard Therapeutics (NASDAQ:ORTX) reported quarterly losses of $(0.04) per share. This is a 86.21 percent increase over losses of $(0.29) per share from the same period last year.
UBS Maintains Buy on Target, Lowers Price Target to $194
UBS analyst Michael Lasser maintains Target (NYSE:TGT) with a Buy and lowers the price target from $205 to $194.